US 10,117,872 B2 · Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake

Abstract

A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.

Claims6

Dependent claims

A method for treating a human patient affected by non-small cell lung cancer or breast cancer, said method comprising subjecting the patient to reduced caloric intake for a period of 24-190 hours while the patient is being treated with a tyrosine kinase inhibitor (TKI),

wherein:
when the patient is affected by non-small cell lung cancer, the TKI is Crizotinib,
when the patient is affected by breast cancer, the TKI is Lapatinib, and
the reduced caloric intake corresponds to less than 300 kcal/day.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

15/129,569Filed 30 Mar 2015

Priority

IT MI2014A053728 Mar 2014

Published

US 2017/0173020 A122 Jun 2017

Granted

6 Nov 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification17 codes

A61K 31/517
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/403
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with…
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof

Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake

Life of this patent

Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake

Life of this patent

Abstract

Claims6